Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.60 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.58 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.58 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.48 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.48 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461287 | 0.99 | ACHE (0.61) | ACHEDRD2SLC6A4SCDHTR2A | |
| SCHEMBL7726651 | 0.92 | ACHE (0.55) | ACHEDRD2SLC6A4HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL1544936 | 0.92 | ACHE (0.54) | ACHEDRD2SLC6A4SCDHTR2A | |
| SCHEMBL7356803 | 0.90 | ACHE (0.55) | ACHEDRD2SLC6A4SCDHTR2A | |
| Hydrochloric Acid SCHEMBL8916694 | 0.89 | SCD (0.50) | ACHEDRD2SLC6A4SCD | |
| Trifluoroacetic Acid SCHEMBL7453133 | 0.88 | ACHE (0.51) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL187372 | 0.87 | SCD (0.51) | ACHEDRD2SLC6A4SCD | |
| SCHEMBL29688619 | 0.87 | SCD (0.51) | ACHEDRD2SLC6A4SCD | |
| SCHEMBL4541441 | 0.87 | ACHE (0.58) | ACHEDRD2SLC6A4SCDHTR2A | |
| SCHEMBL20327895 | 0.84 | ACHE (0.56) | ACHEDRD2SLC6A4SCDHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117700405-B | Preparation method of 6-fluoro-3-piperidin-4-yl-1, 2-benzisoxazole hydrochloride | 山东康诺生物工程有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-117700405-A | Preparation method of 6-fluoro-3-piperidin-4-yl-1, 2-benzisoxazole hydrochloride | 山东康诺生物工程有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-115109056-A | Preparation method of paliperidone | 常州市第四制药厂有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-112830922-B | Preparation method of paliperidone intermediate | 常州恒邦药业有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-111393425-B | Preparation method of 6-fluoro-3-piperidine-4-yl-1, 2-benzisoxazole hydrochloride | 浙江京新药业股份有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-111777601-B | Preparation method of 6-fluoro-3- (4-piperidyl) -1, 2 benzisoxazole hydrochloride | 白银京宇新药业有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-112830922-A | Preparation method of paliperidone intermediate | 常州恒邦药业有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-112624992-A | Purification method of 6-fluoro-3- (4-piperidyl) -1, 2-benzisoxazole hydrochloride | 浙江华海药业股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-111777601-A | Preparation method of 6-fluoro-3- (4-piperidyl) -1, 2 benzisoxazole hydrochloride | 白银京宇新药业有限公司 | 2020-10-16 | — | — | CN | claimed |
| CN-111393425-A | Preparation method of 6-fluoro-3-piperidine-4-yl-1, 2-benzisoxazole hydrochloride | 浙江京新药业股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| US-20120172600-A1 | METHOD FOR PREPARATION OF ILOPERIDONE AND CRYSTALLIZATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2012-07-05 | — | — | US | claimed |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2012-06-28 | — | — | US | claimed |
| WO-2012035554-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE PALIPERIDONE | MEGAFINE PHARMA (P) LTD. (IN) | 2012-03-22 | — | — | WO | claimed |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | US | claimed |
| US-20100311969-A1 | Process For Preparation of Paliperidone | Watson Pharma Private Limited (IN) | 2010-12-09 | — | — | US | claimed |
| WO-2010082110-A2 | NOVEL PROCESS FOR PREPARING PURE 6-FLUORO-3-PIPERIDIN-4-YL-1,2-BENZISOXAZOLE HYDROCHLORIDE AND ITS CONVERSION TO PALIPERIDONE | CADILA PHARMACEUTICALS LTD (IN) | 2010-07-22 | — | — | WO | claimed |
| US-20100130740-A1 | PROCESS FOR PREPARATION OF RISPERIDONE | QILU PHARMACEUTICAL CO. LTD. (CN) | 2010-05-27 | — | — | US | claimed |
| US-20070179163-A1 | Process for the preparation of risperidone | JUBILANT ORGANOSYS LTD. (IN) | 2007-08-02 | — | — | US | claimed |
| EP-1670797-A1 | PROCESS FOR THE PREPARATION OF RISPERIDONE | Jubilant Organosys Limited (IN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030772-A1 | PROCESS FOR THE PREPARATION OF RISPERIDONE | JUBILANT ORGANOSYS LTD. (IN) | 2005-04-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172600-A1 | METHOD FOR PREPARATION OF ILOPERIDONE AND CRYSTALLIZATION METHOD THEREOF | FAP, FIBP, FIP1L1 | ACHE 2487/4885DRD2 4534/4885SLC6A4 4499/4885 |
| US-20070179163-A1 | Process for the preparation of risperidone | CYP2C19, HTR1A, CYP3A7 | ACHE 1910/4885DRD2 193/4885SLC6A4 573/4885 |
| US-20100130740-A1 | PROCESS FOR PREPARATION OF RISPERIDONE | CYP3A7, CYP2C19, HTR7 | ACHE 726/4885DRD2 141/4885SLC6A4 434/4885 |
| US-20100311969-A1 | Process For Preparation of Paliperidone | FIP1L1, HTR3C, HTR4 | ACHE 4192/4885DRD2 87/4885SLC6A4 390/4885 |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | AVPR2, AVPR1B, AVPR1A | ACHE 4692/4885DRD2 307/4885SLC6A4 541/4885 |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | REN, DHPS, AVPR2 | ACHE 4730/4885DRD2 704/4885SLC6A4 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.